Q2 2025 Earnings Call Transcript August 12, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.32. Operator: Good morning, ladies and gentlemen, and ...

NasdaqGM:ALT 1 Year Share Price vs Fair Value Explore Altimmune's Fair Values from the Community and select yours ...

Altimmune Inc (ALT) reports a robust cash reserve and significant progress in drug trials, despite ongoing financial losses ...

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

Altimmune (NASDAQ:ALT) shares surge 8% post-promising Q2 results, driven by pemvidutide's success in metabolic and liver conditions. Read more here.

UBS lowered the firm’s price target on Altimmune (ALT) to $24 from $26 and keeps a Buy rating on the shares. Despite the IMPACT Phase 2b trial setback, UBS still sees a sizeable opportunity for ...

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

Analysts estimate that Altimmune will report an earnings per share (EPS) of $-0.32. Anticipation surrounds Altimmune's ...

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers ...